Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity

David M. Nanus; David P. Kelsen; Roberta Lipperman; Mario Eisenberger

doi:10.1007/BF00175406

Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity

David M. Nanus, David P. Kelsen, Roberta Lipperman, Mario Eisenberger

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Thirty-two patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (1.50 gm/m² daily × 5 days) with uroprotective mesna in a phase II study. Eighteen patients were previously untreated. Of 28 evaluable patients, two (7%) had partial remissions lasting 2+ and 6+ months. Toxicity was predominantly myelosuppression with a median WBC nadir of 1.8 cells/ul. Seven patients required hospitalization for nadir sepsis. Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression.

Original language	English (US)
Pages (from-to)	239-241
Number of pages	3
Journal	Investigational New Drugs
Volume	6
Issue number	3
DOIs	https://doi.org/10.1007/BF00175406
State	Published - Sep 1988
Externally published	Yes

Keywords

epidermoid carcinoma
ifosfamide
phase II

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00175406

Cite this

@article{21fcee5a81174ecb8768f9c96e36b7bc,

title = "Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity",

abstract = "Thirty-two patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (1.50 gm/m2 daily × 5 days) with uroprotective mesna in a phase II study. Eighteen patients were previously untreated. Of 28 evaluable patients, two (7%) had partial remissions lasting 2+ and 6+ months. Toxicity was predominantly myelosuppression with a median WBC nadir of 1.8 cells/ul. Seven patients required hospitalization for nadir sepsis. Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression.",

keywords = "epidermoid carcinoma, ifosfamide, phase II",

author = "Nanus, {David M.} and Kelsen, {David P.} and Roberta Lipperman and Mario Eisenberger",

year = "1988",

month = sep,

doi = "10.1007/BF00175406",

language = "English (US)",

volume = "6",

pages = "239--241",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus

T2 - unexpectant severe toxicity

AU - Nanus, David M.

AU - Kelsen, David P.

AU - Lipperman, Roberta

AU - Eisenberger, Mario

PY - 1988/9

Y1 - 1988/9

N2 - Thirty-two patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (1.50 gm/m2 daily × 5 days) with uroprotective mesna in a phase II study. Eighteen patients were previously untreated. Of 28 evaluable patients, two (7%) had partial remissions lasting 2+ and 6+ months. Toxicity was predominantly myelosuppression with a median WBC nadir of 1.8 cells/ul. Seven patients required hospitalization for nadir sepsis. Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression.

AB - Thirty-two patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (1.50 gm/m2 daily × 5 days) with uroprotective mesna in a phase II study. Eighteen patients were previously untreated. Of 28 evaluable patients, two (7%) had partial remissions lasting 2+ and 6+ months. Toxicity was predominantly myelosuppression with a median WBC nadir of 1.8 cells/ul. Seven patients required hospitalization for nadir sepsis. Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression.

KW - epidermoid carcinoma

KW - ifosfamide

KW - phase II

UR - http://www.scopus.com/inward/record.url?scp=0023821745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023821745&partnerID=8YFLogxK

U2 - 10.1007/BF00175406

DO - 10.1007/BF00175406

M3 - Article

C2 - 3192390

AN - SCOPUS:0023821745

SN - 0167-6997

VL - 6

SP - 239

EP - 241

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this